Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Late-Breaking Trail and Featured Clinical Research Presentations Revealed for ACC Scientific Sessions 2025
Added: 1 year ago Source:  ACC 2025
Watch our comprehensive coverage of ACC 2025's top trials here.The American College of Cardiology has announced the late-breaking trial and featured clinical research presentations for its 74th annual scientific sessions.ACC 2025 will be held from the 29th to 31st March at McCormick Place in Chicago.View the full programme here.Late-Breaking Clinical Trials I (Session 102)Saturday 29th March, 09… View more

Vascular Disease and Surgery

Heart Failure
THT 2026
Start date: Mar 02, 2026 End date: Mar 04, 2026
OverviewTechnology and Heart Failure Therapeutics (THT) 2026 is a three-day, in-person heart failure conference taking place from 2–4 March 2026 at the Omni Boston Hotel at the Seaport, Boston, MA, United States. The meeting is aimed at interventional cardiologists, heart failure specialists, electrophysiologists, structural heart specialists and the wider heart team managing complex heart… View more

Intervention

Heart Failure
AHA 24: The ENDEAVOR Trial
Author(s): Added: 1 year ago
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the… View more

Heart Failure
AHA 24: The EMPEROR-Preserved Trial
Author(s): Andrew JS Coats Added: 1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR… View more

Heart Failure
AHA 24: The VALOR-HCM Trial
Author(s): Milind Y Desai Added: 1 year ago
AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3… View more

Heart Failure
Predicting LVEF Improvement After AF Catheter Ablation
Author(s): Nikhil Ahluwalia , Ahmed Hussain , Rui Providencia , et al Added: 1 year ago

Electrophysiology & Arrhythmia

Heart Failure
ESC HF 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 10 months ago
ESC HF 25 - SCD-PROTECT zeigt hohes Risiko für plötzlichen Herzstillstand (SCA) und plötzlichen Herztod (SCD) während der frühen medikamentösen Therapieoptimierung bei reduzierter LVEF bei Patienten mit neu diagnostizierter nicht-ischämischer Kardiomyopathie oder MI/KHK.Prof Johann Bauersachs (Medizinische Hochschule Hannover, Hannover, DE) diskutiert Ergebnisse aus dem SCD-PROTECT studie, einer… View more

MI/ACS

Heart Failure
STEP: Early Intensive BP Control Shows Long-Term Benefit
Added: 5 months ago Source:  Radcliffe Cardiology
New long-term data from the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial suggests that sustained, intensive blood pressure (BP) control provides greater cardiovascular benefits compared to a delayed approach in older patients with hypertension.¹ The findings also indicate that the earlier intensive treatment is initiated, the greater the reduction in… View more

Demographic

Heart Failure
CNAP and Thermodilution Agreement in Estimating Haemodynamic Parameters
Author(s): Juxerez Maria B Sulit , Armand Delo Tan Added: 1 year ago

Prevention & Chronic Conditions

Vascular Disease and Surgery
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 11 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure